Most Read Articles
Roshini Claire Anthony, 5 days ago

Children who are fully vaccinated against the flu, ie, receive the recommended number of influenza vaccine doses, have a lower risk of acquiring influenza compared with those who are partially vaccinated, a US study found.

06 Jul 2020
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Yesterday
Treatment with levothyroxine appears to have no significant impact on systolic and diastolic heart function in older adults with mild subclinical hypothyroidism as compared with placebo, results of a study have shown.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.

Mavacamten improves symptoms in nonobstructive hypertrophic cardiomyopathy

31 May 2020

The novel myosin inhibitor mavacamten is well tolerated in patients with symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM) and leads to a significant decrease in N-terminal pro–B-type natriuretic peptide (NT-proBNP) and cardiac troponin I (cTnI), which suggests improvement in myocardial wall stress, a study has shown.

“By altering the contractile mechanics of the cardiomyocyte, myosin inhibitors have the potential to modify pathophysiology and improve symptoms associated with HCM,” the investigators said.

This multicentre, double-blind, placebo-controlled, dose-ranging phase II study included 59 adult patients (mean age, 54 years; 58 percent women) with symptomatic nHCM (New York Heart Association functional class II/III), left ventricular ejection fraction (LVEF) ≥55 percent, and NT-proBNP) ≥300 pg/ml.

Participants were randomly assigned 1:1:1 to mavacamten at a pharmacokinetic-adjusted dose (targeting plasma levels: 200 ng/ml, n=19; 500 ng/ml, n=21) or placebo (n=19) for 16 weeks, followed by a washout period of 8 weeks. Initial dose was 5 mg daily with one dose titration at week 6.

Fewer participants on mavacamten had serious adverse events compared to those on placebo (10 percent vs 21 percent). Five patients on mavacamten had reversible reduction in LVEF ≤45 percent.

A substantial reduction in NT-proBNP was observed in the pooled mavacamten group compared to the placebo group (53 percent vs 1 percent), with geometric mean differences of –435 and –6 pg/ml, respectively (p=0.0005). The cTnI also had a significant decrease in the pooled mavacamten vs the placebo group (34 percent vs 4 percent), with geometric mean differences of –0.008 and 0.001 ng/ml, respectively (p=0.009).

“These results set the stage for future studies of mavacamten in this patient population using clinical parameters, including LVEF, to guide dosing,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 5 days ago

Children who are fully vaccinated against the flu, ie, receive the recommended number of influenza vaccine doses, have a lower risk of acquiring influenza compared with those who are partially vaccinated, a US study found.

06 Jul 2020
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Yesterday
Treatment with levothyroxine appears to have no significant impact on systolic and diastolic heart function in older adults with mild subclinical hypothyroidism as compared with placebo, results of a study have shown.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.